1
|
Sancho-Martínez SM, Herrero M, Fontecha-Barriuso M, Mercado-Hernández J, López-Hernández FJ. The Urinary Level of Injury Biomarkers Is Not Univocally Reflective of the Extent of Toxic Renal Tubular Injury in Rats. Int J Mol Sci 2022; 23:ijms23073494. [PMID: 35408856 PMCID: PMC8998362 DOI: 10.3390/ijms23073494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 03/16/2022] [Accepted: 03/21/2022] [Indexed: 12/04/2022] Open
Abstract
Nephrotoxicity is a major cause of intrinsic acute kidney injury (AKI). Because renal tissue damage may occur independently of a reduction in glomerular filtration rate and of elevations in plasma creatinine concentration, so-called injury biomarkers have been proposed to form part of diagnostic criteria as reflective of tubular damage independently of renal function status. We studied whether the urinary level of NGAL, KIM-1, GM2AP, t-gelsolin, and REGIIIb informed on the extent of tubular damage in rat models of nephrotoxicity, regardless of the etiology, moment of observation, and underlying pathophysiology. At a time of overt AKI, urinary biomarkers were measured by Western blot or ELISA, and tubular necrosis was scored from histological specimens stained with hematoxylin and eosin. Correlation and regression studies revealed that only weak relations existed between biomarkers and tubular damage. Due to high interindividual variability in the extent of damage for any given biomarker level, urinary injury biomarkers did not necessarily reflect the extent of the underlying tissue injury in individual rats. We contended, in this work, that further pathophysiological contextualization is necessary to understand the diagnostic significance of injury biomarkers before they can be used for renal tubular damage severity stratification in the context of nephrotoxic and, in general, intrinsic AKI.
Collapse
Affiliation(s)
- Sandra M. Sancho-Martínez
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (S.M.S.-M.); (J.M.-H.)
- Departamento de Fisiología y Farmacología, Universidad de Salamanca (USAL), 37007 Salamanca, Spain; (M.H.); (M.F.-B.)
- Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
- National Network for Kidney Research REDINREN, RD016/0009/0025, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - María Herrero
- Departamento de Fisiología y Farmacología, Universidad de Salamanca (USAL), 37007 Salamanca, Spain; (M.H.); (M.F.-B.)
- Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
| | - Miguel Fontecha-Barriuso
- Departamento de Fisiología y Farmacología, Universidad de Salamanca (USAL), 37007 Salamanca, Spain; (M.H.); (M.F.-B.)
- Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
| | - Joana Mercado-Hernández
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (S.M.S.-M.); (J.M.-H.)
- Departamento de Fisiología y Farmacología, Universidad de Salamanca (USAL), 37007 Salamanca, Spain; (M.H.); (M.F.-B.)
- Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
| | - Francisco J. López-Hernández
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (S.M.S.-M.); (J.M.-H.)
- Departamento de Fisiología y Farmacología, Universidad de Salamanca (USAL), 37007 Salamanca, Spain; (M.H.); (M.F.-B.)
- Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), 37007 Salamanca, Spain
- National Network for Kidney Research REDINREN, RD016/0009/0025, Instituto de Salud Carlos III, 28029 Madrid, Spain
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL), 42002 Soria, Spain
- Group of Biomedical Research on Critical Care (BioCritic), 47003 Valladolid, Spain
- Correspondence:
| |
Collapse
|
2
|
Biochemical and functional characterization of the human tissue kallikrein 9. Biochem J 2017; 474:2417-2433. [DOI: 10.1042/bcj20170174] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/25/2017] [Accepted: 05/30/2017] [Indexed: 12/23/2022]
Abstract
Human tissue kallikrein 9 (KLK9) is a member of the kallikrein-related family of proteases. Despite its known expression profile, much less is known about the functional roles of this protease and its implications in normal physiology and disease. We present here the first data on the biochemical characterization of KLK9, investigate parameters that affect its enzymatic activity (such as inhibitors) and provide preliminary insights into its putative substrates. We show that mature KLK9 is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at the P1 cleavage position. The enzyme activity is enhanced by Mg2+ and Ca2+, but is reversibly attenuated by Zn2+. KLK9 is inhibited in vitro by many naturally occurring or synthetic protease inhibitors. Using a combination of degradomic and substrate specificity assays, we identified candidate KLK9 substrates in two different epithelial cell lines [the non-tumorigenic human keratinocyte cells (HaCaT) and the tumorigenic tongue squamous carcinoma cells (SCC9)]. Two potential KLK9 substrates [KLK10 and midkine (MDK)] were subjected to further validation. Taken together, our data delineate some functional and biochemical properties of KLK9 for future elucidation of the role of this enzyme in health and disease.
Collapse
|
3
|
Filippou P, Korbakis D, Farkona S, Soosaipillai A, Karakosta T, Diamandis EP. A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9. Clin Proteomics 2017; 14:4. [PMID: 28115917 PMCID: PMC5241945 DOI: 10.1186/s12014-017-9140-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Accepted: 01/05/2017] [Indexed: 12/31/2022] Open
Abstract
Background Kallikrein 9 (KLK9) is a member of the human kallikrein-related peptidases family, whose physiological role and implications in disease processes remain unclear. The active form of the enzyme is predicted to have chymotryptic activity. In the present study, we produced for the first time the active recombinant protein and monoclonal antibodies, and developed novel immunoassays for the quantification of free and bound KLK9 in biological samples. Methods The coding sequence of mature KLK9 isoform (mat-KLK9) was expressed in an Expi293F mammalian system and the synthesized polypeptide was purified through a two-step protocol. The purified protein was used as an immunogen for production of monoclonal antibodies in mice. Hybridomas were further expanded and antibodies were purified. Newly-produced monoclonal antibodies were screened for reaction with the KLK9 recombinant protein by a state-of-the-art immunocapture/parallel reaction monitoring mass spectrometry-based methodology. Results Anti-KLK9 antibodies were combined in pairs, resulting in the development of a highly sensitive (limit of detection: 15 pg/mL) and specific (no cross-reactivity with other KLKs) sandwich-type ELISA. Highest KLK9 protein levels were found in tonsil and sweat and lower levels in the heart, kidney and liver. Hybrid immunoassays using an anti-KLK9 antibody for antigen capture and various anti-serine protease inhibitor polyclonal antibodies, revealed the presence of an a1-antichymotrypsin-bound KLK9 isoform in biological samples. Conclusions The ELISAs for free and bound forms of KLK9 may be highly useful for the detection of KLK9 in a broad range of biological samples, thus enabling the clarification of KLK9 function and use as a potential disease biomarker. Electronic supplementary material The online version of this article (doi:10.1186/s12014-017-9140-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Panagiota Filippou
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Clinical Biochemistry, University Health Network, Toronto, Canada
| | - Dimitrios Korbakis
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
| | - Sofia Farkona
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
| | | | - Theano Karakosta
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Clinical Biochemistry, University Health Network, Toronto, Canada
| | - Eleftherios P Diamandis
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Clinical Biochemistry, University Health Network, Toronto, Canada.,Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.,Mount Sinai Hospital, Joseph & Wolf Lebovic Ctr., 60 Murray St [Box 32], Flr 6 - Rm L6-201, Toronto, ON M5T 3L9 Canada
| |
Collapse
|
4
|
Liu SZ, He XM, Zhang X, Zeng FC, Wang F, Zhou XY. Ischemic Preconditioning-Induced SOCS-1 Protects Rat Intestinal Ischemia Reperfusion Injury via Degradation of TRAF6. Dig Dis Sci 2017; 62:105-114. [PMID: 27538408 DOI: 10.1007/s10620-016-4277-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Accepted: 08/10/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND The inflammatory immune response plays an important role in mesenteric ischemia and ischemia-reperfusion injury. Toll-like receptor 4 (TLR4) is a critical receptor in transduction of the inflammatory response and plays an important role in intestinal homeostasis. Tumor necrosis factor receptor-associated factor 6 (TRAF6), known as a key adaptor protein downstream of TLR4, is involved in the inflammatory response by activating multiple apoptotic signaling pathways. However, mechanisms of the suppressor of cytokine signaling-1 (SOCS-1) in regulating cell inflammation and apoptosis are still obscure. OBJECTIVES To investigate the TLR4-TRAF6 signaling pathway in intestinal ischemia and reperfusion injury, as well as SOCS-1 expression after ischemic preconditioning in the rat intestine. METHODS The small bowel ischemia, ischemia-reperfusion, and preconditioning models were induced using ligation of the superior mesenteric artery in male Sprague-Dawley rats; then, the mRNA and protein levels of TLR4, TRAF6, and SOCS-1 were analyzed using real-time PCR, Western blot, and immunohistochemistry, respectively. RESULTS The expression of TLR4 and TRAF6 was gradually increased with increasing intestinal ischemia duration, but increased substantially after ischemia-reperfusion injury. After ischemic preconditioning, TLR4 and TRAF6 expressions decreased; however, expression of SOCS-1 and the TLR4-TRAF6 pathway inhibitor was increased. CONCLUSION These data show that ischemic preconditioning may induce the activation of SOCS-1 to inhibit the TLR4-TRAF6 signaling pathway, thereby playing a protective role in ischemia-reperfusion injury.
Collapse
Affiliation(s)
- Sheng-Zhi Liu
- SouthWest Medical University Clinical Medicine, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China.,Department of Vascular Surgery, The Second People's Hospital of Yibin, 96 North Street, Yi Bin, 644000, Sichuan Province, People's Republic of China
| | - Xue-Mei He
- Medical Research Center, The Affiliated Hospital of SouthWest Medical University, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China
| | - Xu Zhang
- Department of Pathology, The Affiliated Hospital of SouthWest Medical University, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China
| | - Fan-Cai Zeng
- Department of Biochemistry, SouthWest Medical University, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China
| | - Fang Wang
- Department of Vascular and Thyroid Surgery, The Affiliated Hospital of SouthWest Medical University, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China
| | - Xiang-Yu Zhou
- Department of Vascular and Thyroid Surgery, The Affiliated Hospital of SouthWest Medical University, 25 Tai Ping Street, Lu Zhou, 646000, Sichuan Province, People's Republic of China.
| |
Collapse
|